HyliDx Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 6

HyliDx General Information

Description

Operator of a medical diagnostics company intended to support safe and effective assessment and care for critical illnesses anywhere in real-time. The company specializes in developing tools needed to take control of complex diseases, enabling clients to improve the global reach of personalized patient care.

Contact Information

Website
www.hylidx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5310 Canotek Road
  • Unit 28 Floor
  • Ottawa, Ontario K1J 9N5
  • Canada
+1 (613)
Primary Industry
Diagnostic Equipment
Other Industries
Other Devices and Supplies
Other Healthcare Services
Monitoring Equipment
Corporate Office
  • 5310 Canotek Road
  • Unit 28 Floor
  • Ottawa, Ontario K1J 9N5
  • Canada
+1 (613)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

HyliDx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 01-Jan-2025 Completed Generating Revenue
3. Accelerator/Incubator 03-Dec-2024 Completed Generating Revenue
2. Accelerator/Incubator 01-Oct-2024 Completed Generating Revenue
1. Accelerator/Incubator 01-Jan-2022 Completed Generating Revenue
To view HyliDx’s complete valuation and funding history, request access »

HyliDx Patents

HyliDx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025215452-A1 System and method for inexpensive hyperspectral imaging of point-of-care biosensors Pending 31-Jan-2024
EP-4716834-A1 System and method for inexpensive hyperspectral imaging of point-of-care biosensors Pending 31-Jan-2024
WO-2025160679-A1 System and method for inexpensive hyperspectral imaging of point-of-care biosensors Pending 31-Jan-2024
AU-2025206844-A1 System and method of plasma separation and measurement in point-of-care diagnostic cartridges Pending 12-Jan-2024
EP-4716840-A1 System and method of plasma separation and measurement in point-of-care diagnostic cartridges Pending 12-Jan-2024 G01N21/77
To view HyliDx’s complete patent history, request access »

HyliDx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HyliDx Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Archangel Network of Funds Venture Capital Minority
Aventure Capital (VC) Venture Capital Minority
Ventured Synergy Venture Capital Minority
Capital BioVentures Accelerator/Incubator Minority
University of Toronto University
You’re viewing 5 of 6 investors. Get the full list »

HyliDx FAQs

  • When was HyliDx founded?

    HyliDx was founded in 2020.

  • Where is HyliDx headquartered?

    HyliDx is headquartered in Ottawa, Canada.

  • What is the size of HyliDx?

    HyliDx has 6 total employees.

  • What industry is HyliDx in?

    HyliDx’s primary industry is Diagnostic Equipment.

  • Is HyliDx a private or public company?

    HyliDx is a Private company.

  • What is HyliDx’s current revenue?

    The current revenue for HyliDx is .

  • Who are HyliDx’s investors?

    Archangel Network of Funds, Aventure Capital (VC), Ventured Synergy, Capital BioVentures, and University of Toronto are 5 of 6 investors who have invested in HyliDx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process